Related Experiment Videos
Severe Guillain-Barré syndrome in childhood treated with human immune globulin
R C Reisin1, J Pociecha, E Rodriguez
1Department of Pediatric Neurology, Hospital Nacional de Pediatría Prof. J.P. Garrahan, Buenos Aires, Argentina.
Insights
Human immune globulin (IVIg) is safe for treating severe Guillain-Barré syndrome in children. However, IVIg may not benefit children with severely impaired nerve responses, showing limited improvement compared to untreated patients.
Area of Science:
- Neurology
- Immunology
Background:
- Severe Guillain-Barré syndrome (GBS) is a debilitating autoimmune disorder affecting the peripheral nervous system.
- Human immune globulin (IVIg) is a common treatment for GBS, but its efficacy in severe pediatric cases with specific electrodiagnostic findings is debated.
Purpose of the Study:
- To evaluate the effectiveness of IVIg in children with severe GBS based on electrodiagnostic findings.
- To determine if IVIg benefits children with severely impaired nerve conduction.
Main Methods:
- A cohort of 13 children with severe GBS received IVIg (1.9 gm/kg over 2-5 days).
- Patients were categorized into two groups based on electrodiagnostic findings: those with compound motor action potential (CMAP) amplitude >10% of normal and those with inexcitable motor nerves.
- Clinical outcomes were compared between groups and with a historic control group of untreated children.
Main Results:
- Children with inexcitable motor nerves (CMAP amplitude <10% of normal) showed significantly longer recovery times and poorer functional outcomes at 3 and 6 months compared to those with milder electrodiagnostic findings.
- The outcomes for children with inexcitable nerves treated with IVIg were similar to those of untreated historical controls.
- IVIg was found to be safe and easy to administer, without increasing relapse rates.
Conclusions:
- IVIg treatment for severe GBS in children is safe and well-tolerated.
- IVIg does not appear to provide significant clinical benefit for children with severe GBS and inexcitable motor nerves (low CMAP amplitude).
- Electrophysiological findings, specifically CMAP amplitude, are crucial for predicting treatment response to IVIg in pediatric GBS.
Abstract:
Thirteen children with severe Guillain-Barré syndrome were treated with human immune globulin. Patients received a mean total dose of 1.9 gm/kg of human immune globulin for 2 or 5 days. To evaluate the relationship between the response to human immune globulin and electrodiagnostic findings, we compared the clinical outcome of 3 groups of children. The first group consisted of 9 children with electrophysiologic evidence of a mean amplitude of the compound motor action potentials larger than 10% of the lower limit of normal. The second group of 4 children had inexcitable motor nerves. Children in the second group required longer periods to improve one functional grade (mean 67.3 days vs 18.8 days) and to reach grade 2 (219 days vs 32.7 days). Moreover, children in the second group were more disabled after 3 and 6 months, and they all remained with distal atrophy and weakness after 7 months of follow-up. Furthermore, the outcome of children in the second group was no different from that of a historic control of 5 untreated children with severe Guillain-Barré syndrome and similar electrophysiologic findings. Human immune globulin treatment in children with severe Guillain-Barré syndrome is safe, easy to administer, and does not increase the number of relapses. Nevertheless, it does not seem to benefit children with low mean compound motor action potential amplitude.